Fetching results...
0 items found

P0024: Significant reduction of urinary incontinence episodes in patients with neurogenic detrusor overactivity treated with abobotulinumtoxinA (aboBoNT-A): Pooled results of the phase III CONTENT program

A.G. Giannantoni, Siena (IT)
Denys P.1, Giannantoni A.G.2, Thompson C.3, Volteau M.4, Vilain C.5, Kennelly M.6
1Raymond-Poincaré Hospital, Assistance Publique-Hôpitaux de Paris, Dept. of Physical Medicine and Rehabilitation, Garches, France, 2University of Siena, Dept. of Medical and Surgical Sciences and Neurosciences, Functional and Surgical Urology Unit, Siena, Italy, 3June Pharma Consulting, London, United Kingdom, 4Ipsen Pharma, Les Ulis, France, 5Ipsen Pharma, Dept. of Neurology, Boulogne-Billancourt, France, 6Carolinas Medical Center, Dept. of Urology, Charlotte, United States of America
36th Annual EAU Congress
Date – Time - Location
08 July 2021, 08:00 - 09:00, Virtual Room 8
Poster Session 01 - Basic research and clinical developments in chronic pelvic pain, OAB and neurogenic bladder
Benign Lower Urinary Tract Diseases, Neurogenic bladder - Treatment, Drug Treatment
  • © 2023 European Association of Urology
  • Disclaimer